4 Nephrology Headlines You Missed in June 2026

From evolving approaches to chronic kidney disease (CKD) management to new glomerular disease data and a regulatory update from the US Food and Drug Administration (FDA), June delivered several notable developments in nephrology.

Katherine Tuttle, MD, discussed how the "pillared approach" is reshaping CKD care, while Javed Butler, MD, MBA, explored the value of albuminuria in heart failure risk assessment. The month also featured late-breaking TURING trial results evaluating rituximab in minimal change disease and focal segmental glomerulosclerosis (FSGS), as well as an FDA Complete Response Letter for oxylanthanum carbonate in patients with CKD on dialysis.

Here are 4 nephrology headlines you may have missed in June 2026:

Q&A: The Pillared Approach and Reframing Goals of CKD Care, With Katherine Tuttle, MD

Katherine Tuttle, MD, professor of medicine and executive director for research at Providence Healthcare, spoke with HCPLive at the 10th Annual Heart in Diabetes meeting about the evolving “pillared approach” to CKD management and how it is reframing treatment goals in clinical practice.

Over the past several years, a pillared approach to CKD management has gained traction across the field, incorporating renin-angiotensin-aldosterone system inhibition, SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists. Each targets distinct but overlapping pathways, including hemodynamic dysfunction, metabolic dysregulation, inflammation, and fibrosis.

The Value of Albuminuria in Heart Failure Risk Assessment, with Javed Butler, MD, MBA

In an interview at the 10th Annual Heart in Diabetes Meeting, Javed Butler, MD, MBA, president of the Baylor Scott & White Research Institute, discussed the role of albuminuria in heart failure risk assessment and whether urine albumin-to-creatinine ratio (UACR) could serve as a future therapeutic monitoring target.

He also addressed when clinicians should act on elevated albuminuria and how it may refine cardiovascular risk stratification in patients with metabolic disease.

Kidney Compass: Rituximab Cuts Relapse Risk in MCD, FSGS in TURING Trial

In this episode of Kidney Compass, host Brendon Neuen, MBBS, PhD, spoke with Lisa Willcocks, MBBChir, MRCP, PhD, consultant nephrologist at Addenbrooke’s Hospital in Cambridge, United Kingdom, about late-breaking data from the TURING trial presented at the European Renal Association (ERA) Congress in Glasgow, Scotland.

The findings showed rituximab was associated with reduced relapse risk in adults with minimal change disease (MCD) and FSGS, offering new prospective evidence for its role in primary glomerular disease management.

FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis

On June 30, 2026, the FDA issued a CRL to Unicycive Therapeutics for oxylanthanum carbonate in the treatment of hyperphosphatemia in patients with CKD on dialysis.

The agency cited deficiencies at a third-party manufacturing vendor. The company noted the FDA inspection of the facility did not occur during the New Drug Application (NDA) resubmission review. No concerns were raised regarding clinical efficacy or safety data, and no additional data were requested.